News

Prof Ari Melnick receives an ERC Advanced Grant to investigate why a type of lymphoma is more aggressive in women

The European Research Council (ERC) has awarded an Advanced Grant to Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute, for X-SeLECT, a five-year project that will investigate the biological mechanisms behind the female bias observed in a subtype of diffuse large B-cell lymphoma. The research will focus on the role of the X chromosome in how the disease develops and returns after treatment.

Prof Ari Melnick receives an ERC Advanced Grant to investigate why a type of lymphoma is more aggressive in women
Prof Ari Melnick receives an ERC Advanced Grant to investigate why a type of lymphoma is more aggressive in women

Why some cancers progress differently depending on sex is a question that has received little attention. Research led by Prof Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute, has found a clear example in a subtype of diffuse large B-cell lymphoma known as BN2-DLBCL. Within it, the group has identified a novel form of the disease that is highly aggressive specifically in women.

Previous work by Melnick's group points to a mechanism behind this difference: alterations in the normal process that regulates genes on the X chromosome. Female cells generally carry two X chromosomes and one of them is largely silenced through a process called X-chromosome inactivation. This is important since several immune response genes are located on the X chromosome, which explains why auto-immune disorders are more common in women. Preliminary evidence from the team suggest that these mutations disrupt control of these X chromosome immune genes, resulting in formation of autoimmune B cells, that they postulate give rise to these tumours.

Prof Melnick has now been awarded an Advanced Grant by the European Research Council (ERC) to investigate these mechanisms through X-SeLECT, a five-year project. It aims to understand how biological sex influences the origin and development of this lymphoma and how changes in the regulation of the X chromosome may explain why it is more aggressive in women.

ERC Advanced Grants are awarded to established research leaders for ambitious projects with the potential to open new directions in their fields. They are among the most competitive research grants in Europe.

Understanding the role of the X chromosome in a female-biased lymphoma

Melnick's team has found that mutations resulting in shortened (truncated) versions of SPEN, a protein involved in X-chromosome inactivation, cause lethal outcomes in females who also have somatic mutations in another gene called NOTCH2. This was associated with aberrantly high production of key X chromosome genes such as TLR7, which also drives many auto-immune disorders, pointing to a link between lymphomas and auto-immunity. Notably many auto-immune diseases are associated with higher risk of developing lymphomas. The preliminary evidence suggests that these alterations may lie behind the sex bias and X-SeLECT will now study this in depth.

The project will tackle this in several steps. The team will look at how biological sex affects the B cells in which the lymphoma originates, the immune changes that accompany its development and the transformation of these cells into cancer. They will also study how shortened versions of SPEN and of another gene, NOTCH2, work together to destabilise the regulation of genes on the X chromosome and how this deregulation may explain the immune features and the aggressive behaviour seen in women.

A further part of the project will focus on autoimmune B cells and other precursor-like cell populations. The researchers want to understand how these cells allow the disease to persist, including minimal residual disease (the small number of cancer cells that can remain after treatment) and how they contribute to relapse.

To address these questions, the team will combine techniques that analyse the molecular profile of individual cells, such as single-cell multiomics and epigenomics and with high-dimensional flow cytometry. They will perform studies using patient specimens that carry mutations in the genes under study and innovative approaches affording direct observation of living immune cells interacting in real time within normal and malignant lymphoid tissues.

Understanding why cancer progresses differently depending on sex remains a largely unexplored challenge. X-SeLECT involves collaborations with Germans Trias i Pujol University Hospital (Spain), Weill Cornell Medicine (US), Goethe University Frankfurt (Germany), MD Anderson Cancer Center (US), BC Cancer (Canada), as well as the pharmaceutical company AstraZeneca.

About Prof Ari Melnick

Prof Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute, is a recognised leader in the fields of haematological malignancies and cancer epigenetics. Among his major contributions are the first large-scale epigenomic studies in humans, which demonstrated that aberrant epigenetic programming is a hallmark of cancer and that epigenetic diversity is a key determinant of tumour fitness and poor clinical outcomes. In 2020, he received the American Society of Hematology (ASH) Beutler Award for Outstanding Translational Research.

Prof Melnick has also played a foundational role in establishing the importance of epigenetic dysfunction in lymphomagenesis and has developed novel targeted therapies against key lymphoma oncoproteins. Several of these therapeutic approaches have received FDA approval or progressed to phase III clinical trials.



Back